DK1414492T3 - Fremgangsmåde til behandling af multipel myeloma - Google Patents

Fremgangsmåde til behandling af multipel myeloma

Info

Publication number
DK1414492T3
DK1414492T3 DK02742531T DK02742531T DK1414492T3 DK 1414492 T3 DK1414492 T3 DK 1414492T3 DK 02742531 T DK02742531 T DK 02742531T DK 02742531 T DK02742531 T DK 02742531T DK 1414492 T3 DK1414492 T3 DK 1414492T3
Authority
DK
Denmark
Prior art keywords
multiple myeloma
treating multiple
treating
myeloma
Prior art date
Application number
DK02742531T
Other languages
English (en)
Inventor
Robert Lindsay Raison
Rosanne Dorothy Dunn
Boon Hwa Andre Choo
Original Assignee
Immune System Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Therapeutics Ltd filed Critical Immune System Therapeutics Ltd
Application granted granted Critical
Publication of DK1414492T3 publication Critical patent/DK1414492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02742531T 2001-07-06 2002-07-05 Fremgangsmåde til behandling af multipel myeloma DK1414492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6179A AUPR617901A0 (en) 2001-07-06 2001-07-06 Method for treating multiple myeloma
PCT/AU2002/000896 WO2003004056A1 (en) 2001-07-06 2002-07-05 Method for treating multiple myeloma

Publications (1)

Publication Number Publication Date
DK1414492T3 true DK1414492T3 (da) 2008-04-07

Family

ID=3830143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02742531T DK1414492T3 (da) 2001-07-06 2002-07-05 Fremgangsmåde til behandling af multipel myeloma

Country Status (13)

Country Link
US (3) US7344715B2 (da)
EP (1) EP1414492B1 (da)
JP (1) JP4535424B2 (da)
CN (1) CN1551783B (da)
AU (1) AUPR617901A0 (da)
CA (1) CA2461989C (da)
DE (1) DE60223688T2 (da)
DK (1) DK1414492T3 (da)
ES (1) ES2296952T3 (da)
MX (1) MXPA04000130A (da)
NZ (1) NZ530099A (da)
WO (1) WO2003004056A1 (da)
ZA (1) ZA200400959B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
WO2005082409A1 (en) * 2004-02-27 2005-09-09 Pacmab Limited Target for b-cell disorders
ATE503187T1 (de) * 2004-12-23 2011-04-15 Hoffmann La Roche Nachweis eines therapeutischen antikörpers in einem versuchstier
GB0608444D0 (en) * 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
SG175106A1 (en) * 2009-04-07 2011-11-28 Immune System Therapeutics Ltd Method for treating immune disorders
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2462162B1 (en) 2009-08-06 2016-10-12 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CA3043423A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN111643663A (zh) 2013-03-15 2020-09-11 细胞基因公司 修饰的t淋巴细胞
IL255207B2 (en) * 2015-04-23 2023-09-01 Haemalogix Pty Ltd Myeloma antigen chimeric antigen receptors and their uses
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
CA3041284A1 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
JP2023085151A (ja) * 2021-12-08 2023-06-20 株式会社八神製作所 体外ホウ素中性子反応を用いた幹細胞の分取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma

Also Published As

Publication number Publication date
US20040214761A1 (en) 2004-10-28
JP4535424B2 (ja) 2010-09-01
ES2296952T3 (es) 2008-05-01
WO2003004056A1 (en) 2003-01-16
CN1551783A (zh) 2004-12-01
AU2006202148A1 (en) 2006-06-08
US20090263358A1 (en) 2009-10-22
US20080199463A1 (en) 2008-08-21
EP1414492A4 (en) 2005-12-21
JP2005504018A (ja) 2005-02-10
DE60223688T2 (de) 2008-10-30
EP1414492B1 (en) 2007-11-21
MXPA04000130A (es) 2005-06-06
EP1414492A1 (en) 2004-05-06
US7556803B2 (en) 2009-07-07
CA2461989C (en) 2011-11-15
CN1551783B (zh) 2010-11-03
DE60223688D1 (de) 2008-01-03
ZA200400959B (en) 2005-04-26
US7838041B2 (en) 2010-11-23
NZ530099A (en) 2006-04-28
US7344715B2 (en) 2008-03-18
AUPR617901A0 (en) 2001-08-02
CA2461989A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1414492T3 (da) Fremgangsmåde til behandling af multipel myeloma
NO20030241D0 (no) Fremgangsmåte for behandling av multiple brönnintervaller
DK1132569T3 (da) Fremgangsmåde til behandling af en underjordisk formation
NO20043066L (no) Fremgangsmate for kloning av variabel-domene sekvenser
DK1412459T3 (da) Fremgangsmåde til fremstilling af mellemdestillater
DK1016836T3 (da) Fremgangsmåde til tilvejebringelse af köling
DK1252824T3 (da) Fremgangsmåde til forbedring af knoglemineralisering
DK1432319T3 (da) Fremgangsmåde til fremstilling af hundefoder
DK2135957T3 (da) Fremgangsmåde til fremstilling af glucaner
DK1525278T3 (da) Fremgangsmåde til behandling af en overflade
DK1350765T3 (da) Fremgangsmåde til fremstilling af jernoxider
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1314824T3 (da) Fremgangsmåde til konsolidering af jord
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
DK3103443T3 (da) Fremgangsmåde til behandling af primær søvnforstyrrelse
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1309323T3 (da) Fremgangsmåde til behandling af angiogeneserelaterede lidelser
DK1496194T3 (da) Fremgangsmåde til behandling af en brönd
IS6888A (is) Aðferð við meðferð sykursýki af gerð I
DK1400522T3 (da) Forbindelser til behandling af impotens
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer